Announced

EIP Pharma to merge with Diffusion Pharmaceuticals.

Synopsis

EIP Pharma, a privately held clinical-stage company focused on developing treatments for neurodegenerative diseases, agreed to merge with Diffusion Pharmaceuticals, a biotechnology company. Financial terms were not disclosed. “With this proposed merger, we are creating a leading company focused on developing treatments for neurodegenerative diseases, beginning first with neflamapimod for the treatment of dementia with Lewy bodies, the second most common type of dementia after Alzheimer’s disease, and for which there are currently no approved treatments,” John Alam, EIP Pharma CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US